Work

Late Breaking Abstract - A single dose of zumilokibart (APG777) durably suppresses FeNO through 32 weeks in patients with mild-to-moderate asthma

Year: 2026

Type: conference-abstract

Source: European Respiratory Journal

DOI: 10.1183/13993003.congress-2026.pa339

Authors: Mario Castro, Jeremy Cole, James DeAngelo, Erica Winter, Abby Chen, Xioaye Ma, Wei Tew, Sai Thankamony, Myreen Tomas, Glenn Whelan, Claudia Halaby, Carl Dambkowski, Amol Kamboj, Dave Singh

Institutions: University of Kansas Medical Center, University of Manchester, Medicines Evaluation Unit

Language: English

Topic: Asthma and respiratory diseases

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7224445463

Cites:

Cited by:

Related to: 10